An observational study in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-13.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.
3,554 studies on the registry are indexed under Arthritis; 318 are open to participants now.
This study's enrollment of 505 is above the median of 155 across 1,057 observational studies indexed under Arthritis.
Browse Arthritis studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients who are treated with ORENCIA according to the approved indications, and dosage and administration.
Inclusion Criteria:
Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
Drug: Orencia
Safety measured by number of Adverse events and laboratory abnormalities associated with adverse events
Time frame: 24 weeks
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb